molecules-logo

Journal Browser

Journal Browser

Small Molecule Drug Discovery and Development to Face Neurodegenerative Threads

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 367

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy—Pharmaceutical Sciences, University of Bari Aldo Moro, Bari, Italy
Interests: organic synthesis; medicinal and pharmaceutical chemistry; small molecule synthesis; multistep synthesis; enantiomer; fluorine chemistry; sodium channels
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

According to recent studies, neurodegenerative diseases are one of the main causes of disability and death worldwide. They are characterized by age-dependent neuronal depletion in the central nervous system and are often accompanied by the accumulation of misfolded proteins, oxidative stress induction, and neuroinflammation. The most common neurodegenerative disorders are Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. Unfortunately, due to the undefined pathogenesis and the multifaceted nature of neurodegenerative disorders, most pharmacological treatments are mainly symptomatic rather than disease-modifier. Moreover, different side effects are observed, often including sedation, dizziness, and nausea. Despite all the research efforts, the identification of new drugs more potent and with safer profiles is an unmet need.

This Special Issue on “Small molecule drug discovery and development to face neurodegenerative threads” aims to collect both original research articles and reviews on recent advances in the identification of synthetic, semi-synthetic, or naturally occurring small molecules as potential drug candidates to alleviate brain cell damage.

Dr. Maria Maddalena Cavalluzzi
Dr. Giovanni Lentini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegenerative diseases
  • neuroprotection
  • drug discovery
  • synthesis of pharmaceutically relevant compounds
  • isolation and identification of biologically active natural products
  • in vitro, ex vivo, and in vivo biological evaluation
  • molecular docking
  • drug repositioning

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1819 KiB  
Article
Co-Deposited Proteins in Alzheimer’s Disease as a Potential Treasure Trove for Drug Repurposing
by Avgi E. Apostolakou, Dimitra E. Douska, Zoi I. Litou, Ioannis P. Trougakos and Vassiliki A. Iconomidou
Molecules 2025, 30(8), 1736; https://doi.org/10.3390/molecules30081736 - 13 Apr 2025
Viewed by 77
Abstract
Alzheimer’s disease (AD) affects an increasing number of people as the human population ages. The main pathological feature of AD, amyloid plaques, consists of the key protein amyloid-β and other co-deposited proteins. These co-deposited proteins and their protein interactors could hold some additional [...] Read more.
Alzheimer’s disease (AD) affects an increasing number of people as the human population ages. The main pathological feature of AD, amyloid plaques, consists of the key protein amyloid-β and other co-deposited proteins. These co-deposited proteins and their protein interactors could hold some additional functional insights into AD pathophysiology. For this work, proteins found on amyloid plaques were collected from the AmyCo database. A protein–protein and protein–drug interaction network was constructed with data from the IntAct and DrugBank databases, respectively. In total, there were 12 proteins co-deposited on amyloid plaques that reportedly interact with 513 other proteins and are targets of 72 drugs. These drugs were shown to be almost entirely distinct from the panel of drugs currently approved by the FDA for AD and their corresponding protein targets. In conclusion, this work demonstrates the potential for drug repurposing of drugs that target proteins found in amyloid plaques. Full article
Show Figures

Figure 1

Back to TopTop